EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CFTR modulator therapy reshapes airway inflammation in cystic fibrosis: Insights from proteomics and machine learning

Filip Årman, Stefanie Diemer, Lotta J Happonen, Lisa I Påhlman

Journal of Cystic Fibrosis · 2026

DOI: 10.1016/j.jcf.2026.05.002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2026. Verfasst von Filip Årman und 3 weiteren Autor:innen. Beteiligte Einrichtung: BioMS - Swedish National Infrastructure for Biological Mass Spectrometry, Lund University, Lund, Sweden. Hauptthemen laut MEDLINE: Cystic Fibrosis, Machine Learning, Indoles, Cystic Fibrosis Transmembrane Conductance Regulator. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Association of Cystic Fibrosis Research Fund, The Swedish Heart Lung Foundation, Swedish Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: CFTR modulators, including Elexacaftor/Tezacaftor/Ivacaftor (ETI), have markedly improved clinical outcomes for people with cystic fibrosis (pwCF), but the molecular impact on airway inflammation remains incompletely understood. This study aimed to characterise longitudinal changes in airway inflammation and sputum proteomes following ETI treatment. METHODS: Sputum from pwCF (n = 30) was collected before ETI initiation and after 3 and 9-12 months of treatment. Sputum from healthy controls (n = 7) were included for comparison. Proteomes were analysed using data-independent acquisition liquid chromatography tandem mass spectrometry (DIA LC-MS/MS), and cytokines using Mesoscale assays. Differential expression analysis and correlations between airway proteomes and inflammatory cytokines were performed. Machine learning (XGBoost with bootstrapping approach) was applied to identify proteins predictive of ETI response. RESULTS: ETI induced broad proteomic shifts, mainly related to decreased neutrophil degranulation and an increase in anti-proteases. Machine learning predicted proteins linked to RNA splicing, ER stress and lipid transport as contributors to treatment response. IL-1β, IL-8, and TNFα decreased with treatment, correlating with neutrophil-related proteins. In contrast, IL-6 levels increased and correlated with mucin O-glycosylation pathways. Despite these improvements, proteomic and cytokine profiles remained distinct from healthy controls. CONCLUSION: ETI therapy reduces neutrophilic inflammation and restores the protease/antiprotease balance but does not fully normalise airway biology. Machine learning provides novel insights into molecular determinants of ETI response, suggesting a role for RNA splicing, ER stress and lipid metabolism. This dataset provides a valuable resource for further exploration of CF airway biology under ETI therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisMachine LearningIndolesCystic Fibrosis Transmembrane Conductance RegulatorAminophenolsBenzodioxolesPyridinesPyrazolesHumansProteomicsFemaleSputumMaleCytokinesInflammationProteomeDrug CombinationsAdultPyrrolidines

Stichwörter der Autor:innen

Airway inflammationCFTR modulator therapyCystic fibrosisCytokinesElexacaftor/Tezacaftor/IvacaftorLung functionMachine learningProteome

Substanzen

IndolesCystic Fibrosis Transmembrane Conductance RegulatorAminophenolsBenzodioxolesPyridinesCytokinesPyrazolesProteomeDrug Combinationselexacaftor

Autor:innen und Institutionen

  • BioMS - Swedish National Infrastructure for Biological Mass Spectrometry, Lund University, Lund, Sweden.
  • Lund University, Department of Clinical Science Lund, Division of Infection Medicine, Sweden; Skåne University Hospital, Department of Paediatrics, Sweden.
  • Lund University, Department of Clinical Science Lund, Division of Infection Medicine, Sweden; Science for Life Laboratory, Department of Clinical Sciences Lund, Lund University, Sweden.
  • Lund University, Department of Clinical Science Lund, Division of Infection Medicine, Sweden; Wallenberg Centre for Molecular Medicine, Lund, Sweden; Skåne University Hospital, Division of Infectious Diseases, Lund, Swe…

Förderung

  • National Association of Cystic Fibrosis Research Fund
  • The Swedish Heart Lung Foundation
  • Swedish Research Council
  • Alfred Österlunds Foundation
  • Science for Life Laboratory
  • Knut och Alice Wallenbergs Stiftelse
  • Medicinska Fakulteten, Lunds Universitet

Zitieren

APA

Årman, F., Diemer, S., Happonen, L. J., & Påhlman, L. I. (2026). CFTR modulator therapy reshapes airway inflammation in cystic fibrosis: Insights from proteomics and machine learning. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2026.05.002

Vancouver

Årman F, Diemer S, Happonen LJ, Påhlman LI. CFTR modulator therapy reshapes airway inflammation in cystic fibrosis: Insights from proteomics and machine learning. Journal of Cystic Fibrosis. 2026. doi:10.1016/j.jcf.2026.05.002

BibTeX
@article{rman2026,
  author = {Årman, Filip and Diemer, Stefanie and Happonen, Lotta J and Påhlman, Lisa I},
  title = {CFTR modulator therapy reshapes airway inflammation in cystic fibrosis: Insights from proteomics and machine learning},
  journal = {Journal of Cystic Fibrosis},
  year = {2026},
  doi = {10.1016/j.jcf.2026.05.002}
}
Kostenlos starten →